Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario da Coruña (23)

2024

  1. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Lower Urinary Tract Symptoms (LUTS) as a New Clinical Presentation of Histamine Intolerance: A Prevalence Study of Genetic Diamine Oxidase Deficiency

    Journal of Clinical Medicine, Vol. 12, Núm. 21

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2019

  1. HIV co-infection in HTLV-1 carriers in Spain

    Virus Research, Vol. 266, pp. 48-51

2014

  1. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

2013

  1. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 9, pp. 1994-2002

  2. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

2011

  1. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/Hepatitis C virus-coinfected patients treated for chronic hepatitis C

    Clinical Infectious Diseases, Vol. 53, Núm. 12, pp. 1291-1295

2008

  1. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain

    Blood Coagulation and Fibrinolysis, Vol. 19, Núm. 5, pp. 333-340

  2. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2007

  1. Infection by the type 2 human immunodeficiency virus and types 1 and 2 human lymphotropic virus in Spain

    Medicina Clinica

2005

  1. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1

    Clinical Infectious Diseases, Vol. 41, Núm. 2, pp. 227-232

  2. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients

    Journal of Medical Virology, Vol. 77, Núm. 1, pp. 23-28

  3. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain

    Clinical Infectious Diseases, Vol. 41, Núm. 9, pp. 1350-1354

2004

  1. Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations

    Journal of Viral Hepatitis

2003

  1. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

    AIDS, Vol. 17, Núm. 7, pp. 1023-1028

2001

  1. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir

    AIDS, Vol. 15, Núm. 13, pp. 1701-1706

1998

  1. Fibroblastoma de celulas gigantes: Un tumor recurrente en edad pediatrica. Revision de la literatura

    Revista Espanola de Pediatria, Vol. 54, Núm. 322, pp. 349-352